Literature DB >> 19147754

Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism.

Yuanda Song1, Jinhua Wu, Regina A Oyesanya, Zendra Lee, Abir Mukherjee, Xianjun Fang.   

Abstract

PURPOSE: Lysophosphatidic acid (LPA), which is present in ascites of ovarian cancer patients, stimulates expression of vascular endothelial growth factor (VEGF). VEGF is essential for the development and abdominal dissemination of ovarian cancer. We examined how LPA drives VEGF expression to gain a better understanding of tumor angiogenesis under normoxic conditions. EXPERIMENTAL
DESIGN: ELISA, Northern blotting, immunoblotting, quantitative PCR, and promoter reporter analysis in combination with small interfering RNA and pharmacologic inhibitors were used to examine LPA-induced VEGF expression and the underlying mechanisms.
RESULTS: LPA stimulated expression of multiple VEGF variants. A 123-bp fragment proximal to the transcriptional initiation site was identified to be functional promoter region responsible for the response to LPA. The fragment harbors consensus sites for several transcription factors including c-Myc and Sp-1 but not hypoxia-inducible factor-1. Blockade of Rho, ROCK, or c-Myc reduced LPA-dependent VEGF production and promoter activation, suggesting that the G12/13-Rho-ROCK-c-Myc cascade partially contributes to VEGF induction by LPA. More significantly, the multiple Sp-1 sites within the responsive region of the VEGF promoter were essential for LPA-mediated transcription. LPA induced Sp-1 phosphorylation and DNA-binding and transcriptional activities. The silencing of Sp-1 expression with small interfering RNA or inhibition of Sp-1 with pharmacologic inhibitors blocked VEGF production induced by LPA.
CONCLUSIONS: LPA stimulates hypoxia-inducible factor-1-independent VEGF expression to promote tumor angiogenesis through activation of the c-Myc and Sp-1 transcription factors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19147754      PMCID: PMC4872515          DOI: 10.1158/1078-0432.CCR-08-1945

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

1.  Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells.

Authors:  Y L Hu; M K Tee; E J Goetzl; N Auersperg; G B Mills; N Ferrara; R B Jaffe
Journal:  J Natl Cancer Inst       Date:  2001-05-16       Impact factor: 13.506

Review 2.  Botulinum ADP-ribosyltransferase C3: a new tool to study low molecular weight GTP-binding proteins.

Authors:  K Aktories; A Hall
Journal:  Trends Pharmacol Sci       Date:  1989-10       Impact factor: 14.819

3.  Induction of angiogenesis during the transition from hyperplasia to neoplasia.

Authors:  J Folkman; K Watson; D Ingber; D Hanahan
Journal:  Nature       Date:  1989-05-04       Impact factor: 49.962

4.  GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5.

Authors:  Chang-Wook Lee; Richard Rivera; Shannon Gardell; Adrienne E Dubin; Jerold Chun
Journal:  J Biol Chem       Date:  2006-06-14       Impact factor: 5.157

5.  Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.

Authors:  T B Pustilnik; V Estrella; J R Wiener; M Mao; A Eder; M A Watt; R C Bast; G B Mills
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

6.  A conserved family of prolyl-4-hydroxylases that modify HIF.

Authors:  R K Bruick; S L McKnight
Journal:  Science       Date:  2001-10-11       Impact factor: 47.728

7.  Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family.

Authors:  Kyoko Noguchi; Satoshi Ishii; Takao Shimizu
Journal:  J Biol Chem       Date:  2003-04-30       Impact factor: 5.157

8.  Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer.

Authors:  Zendra Lee; Ramona F Swaby; Yuewei Liang; Shuangxing Yu; Shuying Liu; Karen H Lu; Robert C Bast; Gordon B Mills; Xianjun Fang
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

9.  Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients.

Authors:  Y Xu; D C Gaudette; J D Boynton; A Frankel; X J Fang; A Sharma; J Hurteau; G Casey; A Goodbody; A Mellors
Journal:  Clin Cancer Res       Date:  1995-10       Impact factor: 12.531

10.  VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells.

Authors:  T Cohen; H Gitay-Goren; R Sharon; M Shibuya; R Halaban; B Z Levi; G Neufeld
Journal:  J Biol Chem       Date:  1995-05-12       Impact factor: 5.157

View more
  33 in total

1.  Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells.

Authors:  Abir Mukherjee; Jinhua Wu; Suzanne Barbour; Xianjun Fang
Journal:  J Biol Chem       Date:  2012-06-03       Impact factor: 5.157

2.  Ovarian cancer-derived lysophosphatidic acid stimulates secretion of VEGF and stromal cell-derived factor-1 alpha from human mesenchymal stem cells.

Authors:  Eun Su Jeon; Soon Chul Heo; Il Hwan Lee; Yoon Ji Choi; Ji Hye Park; Kyung Un Choi; Do Youn Park; Dong Soo Suh; Man Soo Yoon; Jae Ho Kim
Journal:  Exp Mol Med       Date:  2010-04-30       Impact factor: 8.718

3.  Association of lipid metabolism with ovarian cancer.

Authors:  M Tania; M A Khan; Y Song
Journal:  Curr Oncol       Date:  2010-10       Impact factor: 3.677

4.  Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model.

Authors:  Xiaoyu Xu; Glenn D Prestwich
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

5.  Maternal dietary choline deficiency alters angiogenesis in fetal mouse hippocampus.

Authors:  Mihai G Mehedint; Corneliu N Craciunescu; Steven H Zeisel
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

6.  Lysophosphatidic acids are new substrates for the phosphatase domain of soluble epoxide hydrolase.

Authors:  Ami Oguro; Susumu Imaoka
Journal:  J Lipid Res       Date:  2012-01-03       Impact factor: 5.922

7.  Increased expression of angiogenic genes in the brains of mouse meg3-null embryos.

Authors:  Francesca E Gordon; Catherine L Nutt; Pornsuk Cheunsuchon; Yuki Nakayama; Katelyn A Provencher; Kimberley A Rice; Yunli Zhou; Xun Zhang; Anne Klibanski
Journal:  Endocrinology       Date:  2010-04-14       Impact factor: 4.736

8.  Role of lipid phosphate phosphatase 3 in human aortic endothelial cell function.

Authors:  Zahia Touat-Hamici; Henri Weidmann; Yuna Blum; Carole Proust; Hervé Durand; Francesca Iannacci; Veronica Codoni; Pauline Gaignard; Patrice Thérond; Mete Civelek; Sonia A Karabina; Aldons J Lusis; François Cambien; Ewa Ninio
Journal:  Cardiovasc Res       Date:  2016-09-30       Impact factor: 10.787

Review 9.  Lysophosphatidic acid in vascular development and disease.

Authors:  Siew T Teo; Yun C Yung; Deron R Herr; Jerold Chun
Journal:  IUBMB Life       Date:  2009-08       Impact factor: 3.885

10.  Differential requirement of the epidermal growth factor receptor for G protein-mediated activation of transcription factors by lysophosphatidic acid.

Authors:  Regina A Oyesanya; Susie Greenbaum; David Dang; Zendra Lee; Abir Mukherjee; Jinhua Wu; Paul Dent; Xianjun Fang
Journal:  Mol Cancer       Date:  2010-01-14       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.